Quantum scalar fields in the half-line. A heat kernel/zeta function approach

In this paper we shall study vacuum fluctuations of a single scalar field with Dirichlet boundary conditions in a finite but very long line. The spectral heat kernel, the heat partition function and the spectral zeta function are calculated in terms of Riemann Theta functions, the error function, and hypergeometric PFQ functions.Comment: Latex file, 11 pages, 7 figure

Quantum fluctuations around low-dimensional topological defects

In these Lectures a method is described to analyze the effect of quantum fluctuations on topological defect backgrounds up to the one-loop level. The method is based on the spectral heat kernel/zeta function regularization procedure, and it is first applied to various types of kinks arising in several deformed linear and non-linear sigma models with different numbers of scalar fields. In the second part, the same conceptual framework is constructed for the topological solitons of the planar semilocal Abelian Higgs model, built from a doublet of complex scalar fields and one U(1) gauge field.Comment: 63 pages, 14 figures, expanded version of two lectures given by J.M.G. in 5th International School on Field Theory and Gravitation, Cuiaba, Brazi

On the semiclassical mass of S2{\mathbb S}^2-kinks

One-loop mass shifts to the classical masses of stable kinks arising in a massive non-linear ${\mathbb S}^2$-sigma model are computed. Ultraviolet divergences are controlled using the heat kernel/zeta function regularization method. A comparison between the results achieved from exact and high-temperature asymptotic heat traces is analyzed in depth.Comment: RevTex file, 15 pages, 2 figures. Version to appear in Journal of Physics

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Background: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study aim is to compare the rates of clinical remission at 1?year in patients who discontinue anti-TNF treatment versus those who continue treatment. Methods: This is an ongoing, prospective, double-blind, multicentre, randomized, placebo-controlled study in patients with Crohn?s disease or ulcerative colitis who have achieved clinical remission for ?6?months with an anti-TNF treatment and an immunosuppressant. Patients are being randomized 1:1 to discontinue anti-TNF therapy or continue therapy. Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion. The primary endpoint of the study is sustained clinical remission at 1?year. Other endpoints include endoscopic and radiological activity, patient-reported outcomes (quality of life, work productivity), safety and predictive factors for relapse. The required sample size is 194 patients. In addition to the main analysis (discontinuation versus continuation), subanalyses will include stratification by type of inflammatory bowel disease, phenotype and previous treatment. Biological samples will be obtained to identify factors predictive of relapse after treatment withdrawal. Results: Enrolment began in 2016, and the study is expected to end in 2020. Conclusions: This study will contribute prospective, controlled data on outcomes and predictors of relapse in patients with inflammatory bowel disease after withdrawal of anti-TNF agents following achievement of clinical remission. Clinical trial reference number: EudraCT 2015-001410-1

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.Molecular basis of virus replication, viral pathogenesis and antiviral strategie